Genomic alterations detected by circulating tumor DNA and correlation with response to treatment with elacestrant, an oral selective estrogen receptor degrader, in phase 1 trials in postmenopausal women with ER+/HER2-advanced/metastatic breast cancer

首页> 外文期刊>Intelligence: A Multidisciplinary Journal >Genomic alterations detected by circulating tumor DNA and correlation with response to treatment with elacestrant, an oral selective estrogen receptor degrader, in phase 1 trials in postmenopausal women with ER+/HER2-advanced/metastatic breast cancer

【24h】

Genomic alterations detected by circulating tumor DNA and correlation with response to treatment with elacestrant, an oral selective estrogen receptor degrader, in phase 1 trials in postmenopausal women with ER+/HER2-advanced/metastatic breast cancer

机译：通过循环肿瘤DNA检测的基因组改变与响应次次口服选择性雌激素受体降解剂的肿瘤DNA和相关性，患有ER + / HER2-先进/转移性乳腺癌的绝经后妇女的1期试验中

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Intelligence: A Multidisciplinary Journal》 |2020年第2020期|共3页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类心理学;
关键词

相似文献

外文文献
专利

1. Genomic alterations detected by circulating tumor DNA and correlation with response to treatment with elacestrant, an oral selective estrogen receptor degrader, in phase 1 trials in postmenopausal women with ER+/HER2-advanced/metastatic breast cancer [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：通过循环肿瘤DNA检测的基因组改变与响应次次口服选择性雌激素受体降解剂的肿瘤DNA和相关性，患有ER + / HER2-先进/转移性乳腺癌的绝经后妇女的1期试验中
2. EMERALD: A randomized, open-label, phase 3 trial to evaluate the efficacy and safety of elacestrant (RAD1901), a novel oral selective estrogen receptor degrader (SERD), vs investigator's choice of endocrine therapy for ER+/HER2-advanced breast cancer following CDK4/6 inhibitor therapy [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：祖母绿：一个随机的，开放标签，第3阶段试验，以评估享受新的口服选择性雌激素受体降解剂（SERD），VS调查患者对ER + / HER2晚期乳腺癌的内分泌治疗选择的疗效和安全性 CDK4 / 6抑制剂治疗
3. A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-9545, in postmenopausal women with estrogen receptor-positive (ER+) HER2-negative (HER2-) metastatic breast cancer [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：第一阶段Ⅰ阶段研究，评估口服选择性雌激素受体降解剂（SERD），GDC-9545，雌激素受体阳性（ER +）HER2阴性（HER2-）转移性乳腺癌的绝经后妇女
4. A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using 18F-FES PET/CT imaging [O] . Agnes Jager, Elisabeth G. E. de Vries, C. Willemien Menke-van der Houven van Oordt, 2020

机译：第1B期研究评估了使用18F-FES PET / CT成像的雌激素受体治疗对雌激素受体可用性和雌二醇结合的雌激素受体可用性和雌二醇结合的影响
5. Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER+ Breast Cancer Patient-derived Xenograft Models [O] . Teeru Bihani, Hitisha K. Patel, Heike Arlt, 2017

机译：选择性雌激素受体降解剂（SERD），具有抗肿瘤活性，在多er +乳腺癌患者衍生的异种移植模型中具有抗肿瘤活性

Genomic alterations detected by circulating tumor DNA and correlation with response to treatment with elacestrant, an oral selective estrogen receptor degrader, in phase 1 trials in postmenopausal women with ER+/HER2-advanced/metastatic breast cancer

著录项

相似文献

相关主题

期刊订阅